Athena Countouriotis
CIK 1571469 · President & CEO · last filed 2026-06-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.31M
Companies
8
Total Filings
45
Lifetime Open-Market Net
-$7.13M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IOVA | Director | — | $4.70 | — | $0 | 9 | 2026-06-18 |
| BMRN | Director | 21,040 | $62.07 | $1.31M | $0 | 4 | 2026-06-04 |
| PASG | Director | 945 | $4.57 | $4.3K | $309.9K | 9 | 2026-05-21 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | President & CEO | 0 | $76.01 | $0 | -$7.44M | 8 | 2022-08-17 |
| Cardiff Oncology, Inc. (TROV) Delisted | Director | — | — | — | $0 | 2 | 2019-06-24 |
| Adverum Biotechnologies, Inc. (ADVM) Delisted | SVP, Chief Medical Officer | 15,000 | $4.36 | $65.4K | $0 | 2 | 2018-02-20 |
| HALOZYME THERAPEUTICS, INC. (HTI) Delisted | SVP and Chief Medical Officer | 45,977 | — | — | $0 | 8 | 2017-02-24 |
| AMBIT BIOSCIENCES CORP (AMBI) Delisted | Chief Medical Officer | — | $0.54 | — | $0 | 3 | 2014-11-12 |
Recent Filings · Page 2 of 5
45 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-12-28 | BMRN | Grant (A) | +2,180 | $0 | EDGAR |
| 2023-06-08 | IOVA | Grant (A) | — | $0 | EDGAR |
| 2023-05-26 | PASG | Grant (A) | — | $0 | EDGAR |
| 2022-08-17 | Turning Point Therapeutics, Inc. (TPTX) Delisted | Disp (D) | −110,959 | -$8.43M | EDGAR |
| 2022-06-14 | IOVA | Grant (A) | — | $0 | EDGAR |
| 2022-05-31 | PASG | Grant (A) | — | $0 | EDGAR |
| 2022-02-11 | Turning Point Therapeutics, Inc. (TPTX) Delisted | Mixed | +59,429 | -$107.8K | EDGAR |
| 2021-07-01 | IOVA | Grant (A) | — | $0 | EDGAR |
| 2021-05-28 | PASG | Grant (A) | — | $0 | EDGAR |
| 2021-02-11 | Turning Point Therapeutics, Inc. (TPTX) Delisted | Mixed | — | -$8.06M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.